1. Home
  2. Companies
  3. DXB
  4. Material Events

Dimerix (ASX:DXB) — Material Events

ASX:DXB · 15 articles in the last 12 months · 100% assessed

Click a band to jump to that tier

Major 2 articles Significant 11 articles Notable 2 articles Not Assessed 0 articles
Major ≥90 Significant 75–89 Notable 50–74 Routine <50 Not assessed
Significant Score 75–89
11
Dimerix Surpasses Recruitment Target in Pivotal DMX-200 Phase 3 Trial for FSGSMedium
Dimerix completes adult recruitment in Phase 3 DMX-200 trial for FSGS, surpassing target enrollment
10 Mar 2026 ·Clinical Trial Update ·85
Dimerix Completes Recruitment in Pivotal Phase 3 Trial for Rare Kidney DiseaseMedium
Dimerix completes recruitment in Phase 3 trial of DMX-200 for FSGS, progressing toward FDA discussions
15 Dec 2025 ·Clinical Trial Update ·85
Dimerix Narrows FY25 Loss to $13.25M Amid $55M Licensing Boost and Phase 3 ProgressHigh
Dimerix narrows FY25 loss to $13.25M on AU$55M licensing inflows, advances Phase 3 trial
28 Aug 2025 ·Preliminary Final Report (Appendix 4E) ·85
Dimerix Advances Kidney Disease Trial with Key Proteinuria DataMedium
Dimerix PARASOL data supports proteinuria endpoints for FDA approval in FSGS Phase 3 trial
8 Oct 2025 ·Clinical Data Update ·85
Dimerix’s DMX-200 Secures Orphan Drug Status in Japan, Boosting Rare Kidney Disease HopeMedium
Dimerix's DMX-200 Gains Orphan Drug Status in Japan for Rare Kidney Disease
30 Sept 2025 ·Regulatory Update ·85
Dimerix Confirms Strong Statistical Power in ACTION3 Trial with Proteinuria EndpointMedium
Dimerix confirms ACTION3 trial powered to show DMX-200 proteinuria benefit, continues Phase 3 to final endpoint
28 Apr 2026 ·Clinical Trial Update ·85
Dimerix Advances Phase 3 Trial with Strong Cash and Regulatory MomentumMedium
Dimerix advances Phase 3 trial for DMX-200 with strong cash position and regulatory progress
29 Oct 2025 ·Quarterly Activities Report and Appendix 4C ·85
FDA Endorses Proteinuria Reduction Endpoint in Dimerix’s Pivotal Kidney TrialMedium
FDA Confirms Proteinuria Reduction Endpoint for Dimerix's DMX-200 Phase 3 ACTION3 Trial
24 Dec 2025 ·Regulatory Update ·80
Dimerix Completes Phase 3 Recruitment, Eyes FDA Approval with $38.5M Cash BufferMedium
Dimerix completes Phase 3 trial recruitment, receives FDA input, and reports AU$38.5M cash
29 Jan 2026 ·Quarterly Activities Report and Appendix 4C ·80
Dimerix Confirms Full Adult Recruitment and Secures Funding Talks for Kidney Disease TrialMedium
Dimerix completes adult recruitment in Phase 3 trial, secures funding talks and appoints CFO
30 Apr 2026 ·Quarterly Activities Report and Appendix 4C ·80
Dimerix’s DMX-200 Clears Seventh Safety Review in Pivotal FSGS TrialMedium
Dimerix's ACTION3 Phase 3 Trial Passes Seventh Safety Review with No Concerns
19 Nov 2025 ·Clinical Trial Update ·75
Not Assessed Low Score, or missing data
0

No articles in this tier for the last 12 months.